Hervor Therapeutics
π¨π³China
- Country
- π¨π³China
- Ownership
- Private, Subsidiary
- Established
- 2021-04-26
- Employees
- -
- Market Cap
- -
TIL for Patients With Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: Autologous tumor-infiltrating lymphocyte cells
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hervor Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT06334783
- Locations
- π¨π³
Wowen's hospital, School of medicine, Zhejiang University, Hangzhou, Zhejiang, China
π¨π³Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
π¨π³Nanjing Jinling Hospital, Nanjing, Jiangsu, China
HV-101 for Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: HV-101
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hervor Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05868915
- Locations
- π¨π³
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Β© Copyright 2025. All Rights Reserved by MedPath